Glaukos Corporation (NYSE:GKOS) Receives Consensus Rating of “Moderate Buy” from Analysts

Glaukos Corporation (NYSE:GKOS) has been given an average rating of “Moderate Buy” by the fourteen brokerages that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have given a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $178.0833.

GKOS has been the subject of several recent analyst reports. Needham & Company LLC raised their price target on Glaukos from $150.00 to $201.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. UBS Group began coverage on shares of Glaukos in a research note on Tuesday, July 28th. They set a “neutral” rating and a $150.00 price objective for the company. Wall Street Zen upgraded shares of Glaukos from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. BTIG Research upped their price target on shares of Glaukos from $193.00 to $202.00 and gave the company a “buy” rating in a report on Thursday. Finally, Stifel Nicolaus upped their target price on Glaukos from $175.00 to $190.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th.

Key Headlines Impacting Glaukos

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: BTIG Research raised its price target to $202 from $193 and maintained a “Buy” rating, implying additional upside from the referenced share price. The move reinforces bullish sentiment among analysts. BTIG price target report
• Positive Sentiment: Zacks Research lifted its FY2026 EPS forecast to a loss of $0.43 from a loss of $0.65, its Q3 2026 estimate to a loss of $0.13 from $0.16, and its Q4 estimate to positive $0.03 from a loss of $0.02. The revisions suggest improving near-term earnings trends.
• Positive Sentiment: Zacks also raised its FY2027 EPS estimate to $0.45 from $0.38 and its FY2028 forecast to $1.70 from $1.56. Several later-quarter estimates were increased, pointing to expectations that Glaukos will become increasingly profitable as its products scale.
• Positive Sentiment: Momentum in the iDose TR glaucoma implant and the Epioxa launch is reportedly driving record growth, higher 2026 guidance and expansion of Glaukos’ ophthalmology platform. Zacks growth outlook article
• Neutral Sentiment: Glaukos recently reported revenue of $185.6 million, up 49.6% year over year, while its $0.14 quarterly loss was narrower than expected. However, the company remains unprofitable, and its current-year consensus EPS forecast is still a loss of $0.35.
• Negative Sentiment: Director Gilbert H. Kliman sold 2,500 shares for approximately $475,000 at an average price of $190, reducing his direct ownership by 6.26%. He retained 37,406 shares, so the transaction is a modest negative signal rather than a major change in insider alignment. SEC insider selling filing

Glaukos Stock Up 0.4%

GKOS stock opened at $185.66 on Monday. Glaukos has a twelve month low of $73.16 and a twelve month high of $191.62. The business has a 50 day moving average of $157.38 and a 200 day moving average of $131.62. The company has a quick ratio of 4.46, a current ratio of 5.04 and a debt-to-equity ratio of 0.10. The firm has a market cap of $10.95 billion, a PE ratio of -57.13 and a beta of 0.78.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.The business had revenue of $185.61 million during the quarter, compared to analyst estimates of $150.93 million. During the same quarter in the prior year, the business posted ($0.24) EPS. Glaukos’s revenue for the quarter was up 49.6% compared to the same quarter last year. On average, research analysts forecast that Glaukos will post -0.32 EPS for the current fiscal year.

Insider Buying and Selling at Glaukos

In related news, Director Gilbert H. Kliman sold 2,500 shares of Glaukos stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $190.00, for a total transaction of $475,000.00. Following the transaction, the director owned 37,406 shares in the company, valued at approximately $7,107,140. This trade represents a 6.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Alex R. Thurman sold 20,000 shares of Glaukos stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $180.13, for a total transaction of $3,602,600.00. Following the transaction, the chief financial officer directly owned 43,906 shares in the company, valued at $7,908,787.78. This trade represents a 31.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 113,025 shares of company stock valued at $19,600,006. Corporate insiders own 5.90% of the company’s stock.

Institutional Trading of Glaukos

A number of institutional investors have recently added to or reduced their stakes in GKOS. Allworth Financial LP acquired a new position in shares of Glaukos in the second quarter valued at approximately $28,000. First Horizon Corp lifted its holdings in shares of Glaukos by 1,715.4% during the 4th quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 223 shares in the last quarter. Los Angeles Capital Management LLC purchased a new stake in shares of Glaukos in the fourth quarter worth about $28,000. Larson Financial Group LLC grew its position in Glaukos by 62.0% in the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock valued at $39,000 after acquiring an additional 132 shares in the last quarter. Finally, Parallel Advisors LLC lifted its holdings in Glaukos by 159.2% in the 1st quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 226 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.